Case Overview
MediTech Pharmaceuticals discovered that a competitor was manufacturing and selling a generic version of their patented cancer treatment drug before the patent expiration. The infringement threatened millions in revenue and undermined years of research investment.
Our Strategy
Our intellectual property litigation team developed a comprehensive strategy:
- Conducted detailed forensic analysis of the competitor's product
- Engaged leading technical experts to testify on patent validity
- Filed for preliminary injunction to stop ongoing infringement
- Prepared compelling evidence of wilful infringement
- Developed strong damages model showing substantial harm
Results
We secured a $12 million settlement for our client, including payment for past damages, ongoing royalties, and an agreement that the competitor would cease production of the infringing product. The victory protected MediTech's market position and preserved the value of their intellectual property portfolio.
Client Testimonial
"Oriole Legal's intellectual property team demonstrated exceptional expertise and tenacity. They understood both the legal and scientific aspects of our case, which was crucial to achieving this favorable outcome."
